2
Clinical Trials associated with Mesenchymal stem cell therapy for neurological disorders (Medipost) / Unknown statusNot ApplicableIIT The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
The purpose of the study is to determine the long-term safety and exploratory efficacy of NEUROSTEM®-AD, administered via an open brain surgery to subjects with dementia of the Alzheimer's type, who were eligible for and enrolled in the earlier part of the phase I. Aside from the subjects who completed the earlier part of the Phase I, 3 additional subjects with comparable demographics and disease characteristics as the treatment group will be enrolled into a control group, followed-up for 3 months, and compared for various disease progression indicators with the treatment group.
The hypothesis is that NEUROSTEM®-AD is safe and effective in the treatment of dementia of the Alzheimer's type.
Open-Label, Single-Center, Phase 1 Clinical Trial to Evaluate the Safety and the Efficacy of NEUROTSTEM®-AD in Patients With Dementia of the Alzheimer's Type
The primary purpose of this study is to evaluate the safety and the tolerability of NEUROSTEM®-AD (Human Umbilical Cord Blood Derived Mesenchymal Stem Cells) and to assess the maximum tolerated dose (MTD). This study is also to investigate the efficacy of this study drug in patients with dementia of Alzheimer's type.
100 Clinical Results associated with Mesenchymal stem cell therapy for neurological disorders (Medipost)
100 Translational Medicine associated with Mesenchymal stem cell therapy for neurological disorders (Medipost)
100 Patents (Medical) associated with Mesenchymal stem cell therapy for neurological disorders (Medipost)
100 Deals associated with Mesenchymal stem cell therapy for neurological disorders (Medipost)